It Seems Checkpoint Therapeutics, Inc. (CKPT) Will Go Down. Just Reaches 52 Week Low

May 16, 2018 - By Linda Rogers

The stock of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) hit a new 52-week low and has $3.09 target or 9.00 % below today’s $3.40 share price. The 6 months bearish chart indicates high risk for the $108.85M company. The 1-year low was reported on May, 16 by If the $3.09 price target is reached, the company will be worth $9.80 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 5.26% or $0.17 during the last trading session, reaching $3.4. About 59,543 shares traded. Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) to report earnings on August, 8. They expect $-0.19 EPS, up 32.14 % or $0.09 from last year’s $-0.28 per share. After $-0.35 actual EPS reported by Checkpoint Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -45.71 % EPS growth.

More news for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) were recently published by:, which released: “Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights” on May 10, 2018.‘s article titled: “Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer …” and published on April 18, 2018 is yet another important article.

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company has market cap of $108.85 million. The Company’s pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. It currently has negative earnings. The firm is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase.

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.